<DOC>
	<DOC>NCT00002026</DOC>
	<brief_summary>To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.</brief_summary>
	<brief_title>Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Leukoplakia</mesh_term>
	<mesh_term>Leukoplakia, Hairy</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Topical antifungal therapy. Patient must have: Newly diagnosed clinical and histological hairy leukoplakia. Positive HIV antibody by licensed ELISA or Western blot. Exclusion Criteria Coexisting Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Concurrent Medication: Excluded within 2 weeks of study entry: Systemic antifungal treatment. Excluded within 6 weeks of study entry: Immunomodulators. Systemic antiviral treatment. Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Prior Medication: Excluded within 2 weeks of study entry: Systemic antifungal. Excluded within 6 weeks of study entry: Immunomodulators. Systemic antiviral treatment. Excluded within 8 weeks of study entry: Zidovudine (AZT) or other antiretroviral therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1990</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Leukoplakia, Oral</keyword>
	<keyword>Herpesvirus 4, Human</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>